Skip to content

Vaxcyte

US · PCVX #1630 by market cap Listed 2020
66.96 +0.26 +0.39%
Live - 5344 symbols - heartbeat 160s ago · 2026-10-08 07:36
Pre-market 66.78 -0.27%
After-hours 66.60 -0.54%
Overnight 66.59 -0.55%
Market cap
9.96B
P/B
3.61
EPS
-5.63
Reader sentiment Are you bullish or bearish on PCVX?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 3.54 In line with history 51st percentile
5-year average 3.97 · #319 of 514 in Biotechnology
P/E ratio -8.59 Expensive vs history 82nd percentile
5-year average -13.06 · forward -9.42
P/S ratio --
5-year average 0.00

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Vaxcyte (PCVX) 9.96B -8.78 3.61 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value57.40 Economic moatNone UncertaintyVery High

Trading 14.3% above Morningstar's fair value estimate.

Fair value

Vaxcyte Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 29% premium over our quantitative fair value estimate of $57.40 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's unfavorable dividend structure decreases our fair value estimate. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. Reflecting the firm's dividends is its forward dividend yield of 0%, which ranks in the bottom 30% compared with global peers. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are overvalued.

Alternatively, the firm's balance sheet is reassuring. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 5.7, a core component of leverage, falls in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-10-08 07:36:37 · For reference only, not investment advice and not tailored to your situation.